BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Biopharma Strategy Series – Biopharma’s Next Decade: Views from the Top on Global Strategy and Innovation – on Friday, June 18, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly’s Chief Scientific and Medical Officer and President of Lilly Research Laboratories

The report highlights the trends prevalent in the global hair transplant market and the factors driving the market along with those that act as deterrents to its growth.

The Global medical equipment maintenance market is expected to reach US$ 36,525.26 Mn in 2027 from US$ 16,943.29 Mn in 2018.

The rising number of patients suffering with diabetes and adoption of injection pens over traditional syringes and vials is expected to increase the demand for pen needles over the forecast period.

The report highlights trends prevailing in the market, and the factors driving and hindering the market growth.

INmune Bio, Inc., a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced that the Company has entered into a new $15 million credit facility with Silicon Valley Bank and an affiliate of SVB Financial Group.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced that it has commenced an underwritten public offering of shares of its common stock.

Biogen Inc. (Nasdaq: BIIB) today announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia.

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax, NVX-CoV2373] and an approved influenza vaccine

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that its shareholders, at its meeting on June 9, 2021, elected Milton Morris, PhD, as Director.